Phase 2 Schizophrenia Trial, Recruiting NCT06502964 Sponsor: Alto Neuroscience Condition: Schizophrenia
Back to Schizophrenia

Phase 2 Schizophrenia Trial, Recruiting

NCT06502964
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have had a diagnosis of schizophrenia for at least one year
  • People who have some level of cognitive impairment (difficulties with thinking, memory, or concentration)
  • People who have been on a stable dose of one or two antipsychotic medications for at least 8 weeks before the second study visit
  • People whose schizophrenia symptoms are at a relatively low or controlled level, as measured by a standard symptom rating scale (confirm with trial site for specific score details)
  • People with a body mass index (BMI) between 18.0 and 37.0
  • People who are willing to follow all study procedures and attend all required assessments

Who may not be able to join:

  • People with an unstable physical health condition
  • People who have had a serious worsening of psychiatric symptoms, or who needed to be hospitalised for psychiatric reasons, in the past 6 months
  • People who have been diagnosed with schizoaffective disorder, bipolar disorder, dementia, or an intellectual disability
  • People who are currently experiencing a major depressive episode
  • People who are currently taking mood stabilisers, clozapine, or benzodiazepines on a daily basis
  • People who currently have a moderate or severe substance use disorder

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 650-200-0412

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Alto Neuroscience
Registry
ClinicalTrials.gov
Start date
11 June 2024
Est. completion
1 February 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Theta band activity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov